Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2020

01-08-2020 | Solid Tumor | Review

Functional and metabolic targeting of natural killer cells to solid tumors

Authors: Jiao Wang, Sandro Matosevic

Published in: Cellular Oncology | Issue 4/2020

Login to get access

Abstract

Background

The unique ability of NK cells to target cancer cells without antigen specificity makes them an attractive prospect for immunotherapy of solid tumors. However, the complexity of the tumor microenvironment (TME), particularly its heterogeneity and associated immunosuppressive properties, enables solid tumor cells to escape NK cell immune-surveillance by impairing their infiltration and cytotoxic functions. As a result, NK cells that have been able to infiltrate solid tumors are dysfunctional, exhausted and metabolically and functionally impaired. Understanding the status of NK cells in solid tumors and the interplay between the tumor-promoting functions of the TME and the immunometabolic reprogramming events that NK cells endure as a result is essential to developing approaches to improve the clinical outcome of NK cell-based immunotherapies against solid tumors.

Conclusions

In this review, we address the current knowledge on the presence and immunometabolic roles of NK cells in solid tumors as well as the strategies developed to restore NK cell activities in these conditions, with the ultimate goal of enhancing persistence, trafficking, cytotoxicity and metabolic functions.
Literature
1.
C. Guillerey, N.D. Huntington, M.J. Smyth, Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17, 1025–1036 (2016)PubMed
2.
A.M. Abel, C. Yang, M.S. Thakar, S. Malarkannan, Natural killer cells: Development, maturation, and clinical utilization. Front Immunol 9, 1869 (2018)PubMedPubMedCentral
3.
L. Chiossone, P.Y. Dumas, M. Vienne, E. Vivier, Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 18, 671–688 (2018)PubMed
4.
F. Souza-Fonseca-Guimaraes, J. Cursons, N.D. Huntington, The emergence of natural killer cells as a major target in Cancer immunotherapy. Trends Immunol 40, 142–158 (2019)PubMed
5.
S. Sivori, P. Vacca, G. Del Zotto, E. Munari, M.C. Mingari, L. Moretta, Human NK cells: Surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol 16, 430–441 (2019)
6.
E. Vivier, E. Tomasello, M. Baratin, T. Walzer, S. Ugolini, Functions of natural killer cells. Nat Immunol 9, 503–510 (2008)PubMed
7.
M.A. Cooper, T.A. Fehniger, M.A. Caligiuri, The biology of human natural killer-cell subsets. Trends Immunol 22, 633–640 (2001)PubMed
8.
M.A. Caligiuri, A. Zmuidzinas, T.J. Manley, H. Levine, K.A. Smith, J. Ritz, Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors J Exp Med 171, 1509–1526 (1990)PubMed
9.
J.J. Campbell, S. Qin, D. Unutmaz, D. Soler, K.E. Murphy, M.R. Hodge, L. Wu, E.C. Butcher, Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166, 6477–6482 (2001)PubMed
10.
W. Wang, A.K. Erbe, J.A. Hank, Z.S. Morris, P.M. Sondel, NK cell-mediated antibody-dependent cellular cytotoxicity in Cancer immunotherapy. Front Immunol 6, 368 (2015)PubMedPubMedCentral
11.
Y. Zhu, B. Huang, J. Shi, Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target. Oncotarget. 7, 47163–47172 (2016)PubMedPubMedCentral
12.
E. Vivier, D.H. Raulet, A. Moretta, M.A. Caligiuri, L. Zitvogel, L.L. Lanier, W.M. Yokoyama, S. Ugolini, Innate or adaptive immunity? The example of natural killer cells Science 331, 44–49 (2011)PubMed
13.
14.
S. Lorenzo-Herrero, A. López-Soto, C. Sordo-Bahamonde, A.P. Gonzalez-Rodriguez, M. Vitale, S. Gonzalez, NK cell-based immunotherapy in Cancer metastasis. Cancers 11, 29 (2018)PubMedCentral
15.
Y. Yu, J. Cui, Present and future of cancer immunotherapy: A tumor microenvironmental perspective. Oncol Lett 16, 4105–4113 (2018)PubMedPubMedCentral
16.
M. Wang, J. Zhao, L. Zhang, F. Wei, Y. Lian, Y. Wu, Z. Gong, S. Zhang, J. Zhou, K. Cao, X. Li, W. Xiong, G. Li, Z. Zeng, C. Guo, Role of tumor microenvironment in tumorigenesis. J Cancer 8, 761–773 (2017)PubMedPubMedCentral
17.
M.B. Schaaf, A.D. Garg, P. Agostinis, Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis 9, 115 (2018)PubMedPubMedCentral
18.
S. Damgaci, A. Ibrahim-Hashim, P.M. Enriquez-Navas, S. Pilon-Thomas, A. Guvenis, R.J. Gillies, Hypoxia and acidosis: Immune suppressors and therapeutic targets. Immunology. 154, 354–362 (2018)PubMedPubMedCentral
19.
J.D. Martin, D. Fukumura, D.G. Duda, Y. Boucher, R.K. Jain, Reengineering the tumor microenvironment to alleviate hypoxia and overcome Cancer heterogeneity. Cold Spring Harb Perspect Med 6, a027094 (2016)PubMedPubMedCentral
20.
S.L. Shiao, A.P. Ganesan, H.S. Rugo, L.M. Coussens, Immune microenvironments in solid tumors: New targets for therapy. Genes Dev 25, 2559–2572 (2011)PubMedPubMedCentral
21.
G. Nayyar, Y. Chu, M.S. Cairo, Overcoming resistance to natural killer cell based immunotherapies for solid tumors. Front Oncol 9, 51 (2019)PubMedPubMedCentral
22.
J. L. da Silva, A. L. S. Dos Santos, N. C. C. Nunes, F. de Moraes Lino da Silva, C. G. M. Ferreira, A. C. de Melo, Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol 84, 227–240 (2019)
23.
S.E. Keating, V. Zaiatz-Bittencourt, R.M. Loftus, C. Keane, K. Brennan, D.K. Finlay, C.M. Gardiner, Metabolic reprogramming supports IFN-γ production by CD56bright NK cells. J Immunol 196, 2552–2560 (2016)PubMed
24.
R.P. Donnelly, R.M. Loftus, S.E. Keating, K.T. Liou, C.A. Biron, C.M. Gardiner, D.K. Finlay, mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol 193, 4477–4484 (2014)PubMedPubMedCentral
25.
S.M. Almutairi, A.K. Ali, W. He, D.S. Yang, P. Ghorbani, L. Wang, M.D. Fullerton, S.H. Lee, Interleukin-18 up-regulates amino acid transporters and facilitates amino acid-induced mTORC1 activation in natural killer cells. J Biol Chem 294, 4644–4655 (2019)PubMedPubMedCentral
26.
Y. Mao, V. van Hoef, X. Zhang, E. Wennerberg, J. Lorent, K. Witt, L. Masvidal, S. Liang, S. Murray, O. Larsson, R. Kiessling, A. Lundqvist, IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood 128, 1475–1489 (2016)
27.
A. Marçais, J. Cherfils-Vicini, C. Viant, S. Degouve, S. Viel, A. Fenis, J. Rabilloud, K. Mayol, A. Tavares, J. Bienvenu, Y.G. Gangloff, E. Gilson, E. Vivier, T. Walzer, The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol 15, 749–757 (2014)PubMedPubMedCentral
28.
Y. Wu, Z. Tian, H. Wei, Developmental and functional control of natural killer cells by cytokines. Front Immunol 8, 930 (2017)PubMedPubMedCentral
29.
N.W. Zwirner, A. Ziblat, Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: The case of IL-27. Front Immunol 8, 25 (2017)PubMedPubMedCentral
30.
J. Rautela, N.D. Huntington, IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol 44, 1–6 (2017)PubMed
31.
M. Patidar, N. Yadav, S.K. Dalai, Interleukin 15: A key cytokine for immunotherapy. Cytokine Growth Factor Rev 31, 49–59 (2016)PubMed
32.
N. Nandagopal, A.K. Ali, A.K. Komal, S.H. Lee, The critical role of IL-15–PI3K–mTOR pathway in natural killer cell effector functions. Front Immunol 5, 187 (2014)PubMedPubMedCentral
33.
A.K. Ali, N. Nandagopal, S.H. Lee, IL-15–PI3K–AKT–mTOR: A critical pathway in the life journey of natural killer cells. Front Immunol 6, 355 (2015)PubMedPubMedCentral
34.
R. Sharma, A. Das, IL-2 mediates NK cell proliferation but not hyperactivity. Immunol Res 66, 151–157 (2018)PubMed
35.
A.C. Jaime-Ramirez, B.L. Mundy-Bosse, S. Kondadasula, N.B. Jones, J.M. Roda, A. Mani, R. Parihar, V. Karpa, T.L. Papenfuss, K.M. LaPerle, E. Biller, A. Lehman, A.R. Chaudhury, D. Jarjoura, R.W. Burry, W.E. Carson, IL-12 enhances the antitumor actions of Trastuzumab via NK cell IFN-γ production. J Immunol 186, 3401–3409 (2011)PubMedPubMedCentral
36.
Y.H. Choi, E.J. Lim, S.W. Kim, Y.W. Moon, K.S. Park, H.J. An, IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells. J. ImmunoTher. Cancer 7, 168 (2019)PubMedPubMedCentral
37.
A. Ziblat, C.I. Domaica, R.G. Spallanzani, X.L.R. Iraolagoitia, L.E. Rossi, D.E. Avila, N.I. Torres, M.B. Fuertes, N.W. Zwirner, IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol 45, 192–202 (2015)PubMed
38.
N.W. Zwirner, C.I. Domaica, Cytokine regulation of natural killer cell effector functions. Biofactors 36, 274–288 (2010)
39.
M.P. Keppel, N. Topcagic, A.Y. Mah, T.P. Vogel, M.A. Cooper, Activation-specific metabolic requirements for NK cell IFN-γ production. J Immunol 194, 1954–1962 (2015)PubMedPubMedCentral
40.
A.Y. Mah, M.A. Cooper, Metabolic regulation of natural killer cell IFN-γ production. Crit Rev Immunol 36, 131–147 (2016)PubMedPubMedCentral
41.
A.M. Chambers, K.B. Lupo, S. Matosevic, Tumor microenvironment-induced Immunometabolic reprogramming of natural killer cells. Front Immunol 9, 2517 (2018)PubMedPubMedCentral
42.
W. Salzberger, G. Martrus, K. Bachmann, H. Goebels, L. Heß, M. Koch, A. Langeneckert, S. Lunemann, K.J. Oldhafer, C. Pfeifer, T. Poch, L. Richert, C. Schramm, R. Wahib, M.J. Bunders, M. Altfeld, Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. PLoS One 13, e0201170 (2018)PubMedPubMedCentral
43.
J. Cong, X. Wang, X. Zheng, D. Wang, B. Fu, R. Sun, Z. Tian, H. Wei, Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung Cancer progression. Cell Metab 28, 243–255 (2018)PubMed
44.
K. Slattery, V. Zaiatz-Bittencourt, E. Woods, K. Brennan, S. Marks, S. Chew, M. Conroy, C. Goggin, J. Kennedy, D.K. Finlay, C.M. Gardiner, TGFβ drives mitochondrial dysfunction in peripheral blood NK cells during metastatic breast cancer. BioRxiv 648501 (2019)
45.
A.M. Chambers, J. Wang, K.B. Lupo, H. Yu, N.M. Atallah Lanman, S. Matosevic, Adenosinergic signaling alters natural killer cell functional responses. Front Immunol 9, 2533 (2018)PubMedPubMedCentral
46.
S. Matosevic, A.M. Chambers, Immunometabolic dysfunction of natural killer cells mediated by the hypoxia-CD73 axis in solid tumors. Front Mol Biosci 6, 60 (2019)PubMedPubMedCentral
47.
M. Balsamo, C. Manzini, G. Pietra, F. Raggi, F. Blengio, M.C. Mingari, L. Varesio, L. Moretta, M.C. Bosco, M. Vitale, Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol 43, 2756–2764 (2013)PubMed
48.
S.Y. Velásquez, D. Killian, J. Schulte, C. Sticht, M. Thiel, H.A. Lindner, Short-term hypoxia synergizes with interleukin 15 priming in driving glycolytic gene transcription and supports human natural killer cell activities. J Biol Chem 291, 12960–12977 (2016)PubMedPubMedCentral
49.
E. Krzywinska, C. Kantari-Mimoun, Y. Kerdiles, M. Sobecki, T. Isagawa, D. Gotthardt, M. Castells, J. Haubold, C. Millien, T. Viel, B. Tavitian, N. Takeda, J. Fandrey, E. Vivier, V. Sexl, C. Stockmann, Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Nat Commun 8, 1597 (2017)PubMedPubMedCentral
50.
Y. Feng, Y. Xiong, T. Qiao, X. Li, L. Jia, Y. Han, Lactate dehydrogenase a: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med 7, 6124–6136 (2018)PubMedPubMedCentral
51.
C. Harmon, M.W. Robinson, F. Hand, D. Almuaili, K. Mentor, D.D. Houlihan, E. Hoti, L. Lynch, J. Geoghegan, C. O’Farrelly, Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res. 7, 335–346 (2019)PubMed
52.
J. Wang, S. Matosevic, NT5E/CD73 as correlative factor of patient survival and natural killer cell infiltration in glioblastoma. J Clin Med 8, 1526 (2019)PubMedCentral
53.
J.S. Schleypen, N. Baur, R. Kammerer, P.J. Nelson, K. Rohrmann, E.F. Gröne, M. Hohenfellner, A. Haferkamp, H. Pohla, D.J. Schendel, C.S. Falk, E. Noessner, Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12, 718–725 (2006)PubMed
54.
J.S. Schleypen, M. Von Geldern, E.H. Weiss, N. Kotzias, K. Rohrmann, D.J. Schendel, C.S. Falk, H. Pohla, Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 106, 905–912 (2003)PubMed
55.
P.I. Tartter, B. Steinberg, D.M. Barron, G. Martinelli, The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 122, 1264–1268 (1987)PubMed
56.
C. Denkert, G. von Minckwitz, S. Darb-Esfahani, B. Lederer, B. I. Heppner, K. E. Weber, J. Budczies, J. Huober, F. Klauschen, J. Furlanetto, W. D. Schmitt, J. U. Blohmer, T. Karn, B. M. Pfitzner, S. Kümmel, K. Engels, A. Schneeweiss, A. Hartmann, A. Noske, P. A. Fasching, C. Jackisch, M. van Mackelenbergh, P. Sinn, C. Schem, C. Hanusch, M. Untch, S. Loibl, Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19, 40–50 (2018)
57.
R. Salgado, C. Denkert, C. Campbell, P. Savas, P. Nuciforo, P. Nucifero, C. Aura, E. de Azambuja, H. Eidtmann, C.E. Ellis, J. Baselga, M.J. Piccart-Gebhart, S. Michiels, I. Bradbury, C. Sotiriou, S. Loi, Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast Cancer treated with Lapatinib and Trastuzumab: A secondary analysis of the NeoALTTO trial. JAMA Oncol 1, 448–454 (2015)PubMedPubMedCentral
58.
R. Gennari, S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, B. Oliviero, B. Ballardini, G. Da Prada, A. Zambelli, A. Costa, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10, 5650–5655 (2004)PubMed
59.
A. Muntasell, F. Rojo, S. Servitja, C. Rubio-Perez, M. Cabo, D. Tamborero, M. Costa-García, M. Martínez-Garcia, S. Menéndez, I. Vazquez, A. Lluch, A. Gonzalez-Perez, A. Rovira, M. López-Botet, J. Albanell, NK cell infiltrates and HLA class I expression in primary HER2+ breast Cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res 25, 1535–1545 (2019)PubMed
60.
J. Cursons, F. Souza-Fonseca-Guimaraes, M. Foroutan, A. Anderson, F. Hollande, S. Hediyeh-Zadeh, A. Behren, N.D. Huntington, M.J. Davis, A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res 7, 1162–1174 (2019)PubMed
61.
A. Gras Navarro, A.T. Björklund, M. Chekenya, Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol 6, 102 (2015)
62.
A. Jiménez-Sánchez, D. Memon, S. Pourpe, H. Veeraraghavan, Y. Li, H.A. Vargas, M.B. Gill, K.J. Park, O. Zivanovic, J. Konner, J. Ricca, D. Zamarin, T. Walther, C. Aghajanian, J.D. Wolchok, E. Sala, T. Merghoub, A. Snyder, M.L. Miller, Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian Cancer patient. Cell 170, 927–938 (2017)
63.
J. Kmiecik, J. Zimmer, M. Chekenya, Natural killer cells in intracranial neoplasms: Presence and therapeutic efficacy against brain tumours. J Neuro-Oncol 116, 1–9 (2014)
64.
I. Golán, L. Rodríguez de la Fuente, J.A. Costoya, NK Cell-Based Glioblastoma Immunotherapy Cancers 10, 522 (2018)
65.
W. Tomaszewski, L. Sanchez-Perez, T.F. Gajewski, J.H. Sampson, Brain tumor microenvironment and host state: Implications for immunotherapy. Clin Cancer Res 25, 4202–4210 (2019)PubMed
66.
R. Castriconi, A. Dondero, F. Bellora, L. Moretta, A. Castellano, F. Locatelli, M.V. Corrias, A. Moretta, C. Bottino, Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells. J Immunol 190, 5321–5328 (2013)PubMed
67.
I. Melero, A. Rouzaut, G.T. Motz, G. Coukos, T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy. Cancer Discov 4, 522–526 (2014)
68.
J. Eckl, A. Buchner, P.U. Prinz, R. Riesenberg, S.I. Siegert, R. Kammerer, P.J. Nelson, E. Noessner, Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med 90, 55–66 (2012)PubMed
69.
S.P. Schantz, N.G. Ordonez, Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer. Nat Immun Cell Growth Regul 10, 278–288 (1991)PubMed
70.
P. Carrega, B. Morandi, R. Costa, G. Frumento, G. Forte, G. Altavilla, G.B. Ratto, M.C. Mingari, L. Moretta, G. Ferlazzo, Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112, 863–875 (2008)PubMed
71.
K.B. Lupo, S. Matosevic, Natural killer cells as allogeneic effectors in adoptive Cancer immunotherapy. Cancers 11, 6 (2019)
72.
A. Stojanovic, A. Cerwenka, Natural killer cells and solid tumors. J Innate Immun 3, 355–364 (2011)PubMed
73.
G. Habif, A. Crinier, P. André, E. Vivier, E. Narni-Mancinelli, Targeting natural killer cells in solid tumors. Cell Mol Immunol 16, 415–422 (2019)PubMedPubMedCentral
74.
T.N. Dao, S. Matosevic, Immunometabolic responses of natural killer cells to inhibitory tumor microenvironment checkpoints. Immunometabolism 1, e190003 (2019)
75.
A. Zingoni, R. Molfetta, C. Fionda, A. Soriani, R. Paolini, M. Cippitelli, C. Cerboni, A. Santoni, NKG2D and Its Ligands: “One for All, All for One.” Front Immunol 9, 476 (2018)
76.
C.A. Crane, S.J. Han, J.J. Barry, B.J. Ahn, L.L. Lanier, A.T. Parsa, TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-Oncology 12, 7–13 (2009)
77.
J.C. Lee, K.M. Lee, D.W. Kim, D.S. Heo, Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172, 7335–7340 (2004)PubMed
78.
C.D. Cluxton, C. Spillane, S.A. O’Toole, O. Sheils, C.M. Gardiner, J.J. O’Leary, Suppression of natural killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade. PLoS One 14, e0211538 (2019)PubMedPubMedCentral
79.
H. Saito, T. Osaki, M. Ikeguchi, Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer 15, 27–33 (2012)PubMed
80.
D. Schmiedel, O. Mandelboim, NKG2D ligands-critical targets for Cancer immune escape and therapy. Front Immunol 9, 2040 (2018)PubMedPubMedCentral
81.
E.M. de Kruijf, A. Sajet, J.G.H. van Nes, H. Putter, V.T.H.B.M. Smit, R.A. Eagle, I. Jafferji, J. Trowsdale, G.J. Liefers, C.J.H. van de Velde, P.J.K. Kuppen, NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: An observational study. BMC Cancer 12, 24 (2012)
82.
G. Chitadze, J. Bhat, M. Lettau, O. Janssen, D. Kabelitz, Generation of soluble NKG2D ligands: Proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 78, 120–129 (2013)PubMed
83.
K. Kono, A. Takahashi, F. Ichihara, H. Sugai, H. Fujii, Y. Matsumoto, Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62, 5813–5817 (2002)PubMed
84.
G. Peruzzi, L. Femnou, A. Gil-Krzewska, F. Borrego, J. Weck, K. Krzewski, J.E. Coligan, Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J Immunol 191, 1883–1894 (2013)PubMedPubMedCentral
85.
R. Romee, B. Foley, T. Lenvik, Y. Wang, B. Zhang, D. Ankarlo, X. Luo, S. Cooley, M. Verneris, B. Walcheck, J. Miller, NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599–3608 (2013)
86.
P. Darvin, S.M. Toor, V. Sasidharan Nair, E. Elkord, Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med 50, 165 (2018)PubMedCentral
87.
S.C. Wei, C.R. Duffy, J.P. Allison, Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8, 1069–1086 (2018)
88.
T. Kamiya, S.V. Seow, D. Wong, M. Robinson, D. Campana, Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest 130, 2094–2106 (2019)
89.
E. Le Dréan, F. Vély, L. Olcese, A. Cambiaggi, S. Guia, G. Krystal, N. Gervois, A. Moretta, F. Jotereau, E. Vivier, Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: Association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol 28, 264–276 (1998)PubMed
90.
F. Borrego, M. Masilamani, J. Kabat, T.B. Sanni, J.E. Coligan, The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol 42, 485–488 (2005)PubMed
91.
M. Valés-Gómez, H.T. Reyburn, R.A. Erskine, M. López-Botet, J.L. Strominger, Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-a and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 18, 4250–4260 (1999)PubMedPubMedCentral
92.
H. Wada, N. Matsumoto, K. Maenaka, K. Suzuki, K. Yamamoto, The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur J Immunol 34, 81–90 (2004)PubMed
93.
C. Sun, J. Xu, Q. Huang, M. Huang, H. Wen, C. Zhang, J. Wang, J. Song, M. Zheng, H. Sun, H. Wei, W. Xiao, R. Sun, Z. Tian, High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunol 6, e1264562 (2017)
94.
S. Platonova, J. Cherfils-Vicini, D. Damotte, L. Crozet, V. Vieillard, P. Validire, P. André, M.C. Dieu-Nosjean, M. Alifano, J.F. Régnard, W.H. Fridman, C. Sautès-Fridman, I. Cremer, Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71, 5412–5422 (2011)PubMed
95.
M. Gillard-Bocquet, C. Caer, N. Cagnard, L. Crozet, M. Perez, W.H. Fridman, C. Sautès-Fridman, I. Cremer, Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol 4, 19 (2013)PubMedPubMedCentral
96.
E. Mamessier, A. Sylvain, M.L. Thibult, G. Houvenaeghel, J. Jacquemier, R. Castellano, A. Gonçalves, P. André, F. Romagné, G. Thibault, P. Viens, D. Birnbaum, F. Bertucci, A. Moretta, D. Olive, Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121, 3609–3622 (2011)PubMedPubMedCentral
97.
K. Stringaris, T. Sekine, A. Khoder, A. Alsuliman, B. Razzaghi, R. Sargeant, J. Pavlu, G. Brisley, H. de Lavallade, A. Sarvaria, D. Marin, S. Mielke, J.F. Apperley, E.J. Shpall, A.J. Barrett, K. Rezvani, Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 99, 836–847 (2014)
98.
P. André, C. Denis, C. Soulas, C. Bourbon-Caillet, J. Lopez, T. Arnoux, M. Bléry, C. Bonnafous, L. Gauthier, A. Morel, B. Rossi, R. Remark, V. Breso, E. Bonnet, G. Habif, S. Guia, A. I. Lalanne, C. Hoffmann, O. Lantz, J. Fayette, A. Boyer-Chammard, R. Zerbib, P. Dodion, H. Ghadially, M. Jure-Kunkel, Y. Morel, R. Herbst, E. Narni-Mancinelli, R. B. Cohen, E. Vivier, Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731–1743 (2018)
99.
M. Benevolo, M. Mottolese, E. Tremante, F. Rollo, M.G. Diodoro, C. Ercolani, I. Sperduti, E. Lo Monaco, M. Cosimelli, P. Giacomini, High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 9, 184 (2011)PubMedPubMedCentral
100.
T. van Hall, P. André, A. Horowitz, D. F. Ruan, L. Borst, R. Zerbib, E. Narni-Mancinelli, S. H van der Burg, E. Vivier. Monalizumab: Inhibiting the novel immune checkpoint NKG2A. J ImmunoTher Cancer 7, 263 (2019)
101.
B.C. Creelan, S.J. Antonia, The NKG2A immune checkpoint — A new direction in cancer immunotherapy. Nat Rev Clin Oncol 16, 277 (2019)PubMed
102.
C. Pfeifer, A.J. Highton, S. Peine, J. Sauter, A.H. Schmidt, M.J. Bunders, M. Altfeld, C. Körner, Natural killer cell education is associated with a distinct glycolytic profile. Front Immunol 9, 3020 (2018)PubMedPubMedCentral
103.
Y. Liu, Y. Cheng, Y. Xu, Z. Wang, X. Du, C. Li, J. Peng, L. Gao, X. Liang, C. Ma, Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene 36, 6143–6153 (2017)
104.
J. Hsu, J.J. Hodgins, M. Marathe, C.J. Nicolai, M.C. Bourgeois-Daigneault, T.N. Trevino, C.S. Azimi, A.K. Scheer, H.E. Randolph, T.W. Thompson, L. Zhang, A. Iannello, N. Mathur, K.E. Jardine, G.A. Kirn, J.C. Bell, M.W. McBurney, D.H. Raulet, M. Ardolino, Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest 128, 4654–4668 (2018)PubMedPubMedCentral
105.
D. Sarhan, K.L. Hippen, A. Lemire, S. Hying, X. Luo, T. Lenvik, J. Curtsinger, Z. Davis, B. Zhang, S. Cooley, F. Cichocki, B.R. Blazar, J.S. Miller, Adaptive NK cells resist regulatory T-cell suppression driven by IL37. Cancer Immunol Res 6, 766–775 (2018)
106.
Y. Huang, Z. Chen, J.H. Jang, M.S. Baig, G. Bertolet, C. Schroeder, S. Huang, Q. Hu, Y. Zhao, D.E. Lewis, L. Qin, M.X. Zhu, D. Liu, PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse. J Allergy Clin Immunol 142, 1311–1321 (2018)PubMedPubMedCentral
107.
A. Beldi-Ferchiou, M. Lambert, S. Dogniaux, F. Vély, E. Vivier, D. Olive, S. Dupuy, F. Levasseur, D. Zucman, C. Lebbé, D. Sène, C. Hivroz, S. Caillat-Zucman, PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7, 72961–72977 (2016)
108.
S.J. Blake, W.C. Dougall, J.J. Miles, M.W.L. Teng, M.J. Smyth, Molecular pathways: Targeting CD96 and TIGIT for Cancer immunotherapy. Clin Cancer Res 22, 5183–5188 (2016)PubMed
109.
N. Stanietsky, H. Simic, J. Arapovic, A. Toporik, O. Levy, A. Novik, Z. Levine, M. Beiman, L. Dassa, H. Achdout, N. Stern-Ginossar, P. Tsukerman, S. Jonjic, O. Mandelboim, The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106, 17858–17863 (2009)PubMedPubMedCentral
110.
W.C. Dougall, S. Kurtulus, M.J. Smyth, A.C. Anderson, TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy. Immunol Rev 276, 112–120 (2017)PubMed
111.
Q. Zhang, J. Bi, X. Zheng, Y. Chen, H. Wang, W. Wu, Z. Wang, Q. Wu, H. Peng, H. Wei, R. Sun, Z. Tian, Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19, 723–732 (2018)PubMed
112.
K.F. Stengel, K. Harden-Bowles, X. Yu, L. Rouge, J. Yin, L. Comps-Agrar, C. Wiesmann, J.F. Bazan, D.L. Eaton, J.L. Grogan, Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A 109, 5399–5404 (2012)PubMedPubMedCentral
113.
S. Liu, H. Zhang, M. Li, D. Hu, C. Li, B. Ge, B. Jin, Z. Fan, Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ 20, 456–464 (2013)PubMed
114.
A.M. Farkas, F. Audenet, H. Anastos, M. Galsky, J. Sfakianos, N. Bhardwaj, Tim-3 and TIGIT mark natural killer cells susceptible to effector dysfunction in human bladder cancer. J Immunol 200, 124.14 (2018)
115.
L.E. Lucca, P.P. Axisa, E.R. Singer, N.M. Nolan, M. Dominguez-Villar, D.A. Hafler, TIGIT signaling restores suppressor function of Th1 Tregs. JCI Insight 4, e124427 (2019)PubMedCentral
116.
M. Molgora, E. Bonavita, A. Ponzetta, F. Riva, M. Barbagallo, S. Jaillon, B. Popović, G. Bernardini, E. Magrini, F. Gianni, S. Zelenay, S. Jonjić, A. Santoni, C. Garlanda, A. Mantovani, IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity. Nature 551, 110–114 (2017)
117.
L. Long, X. Zhang, F. Chen, Q. Pan, P. Phiphatwatchara, Y. Zeng, H. Chen, The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy. Genes Cancer 9, 176–189 (2018)PubMedPubMedCentral
118.
B. Huard, M. Tournier, F. Triebel, LAG-3 does not define a specific mode of natural killing in human. Immunol Lett 61, 109–112 (1998)PubMed
119.
A.C. Anderson, N. Joller, V.K. Kuchroo, Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016)
120.
P.A. Ascierto, I. Melero, S. Bhatia, P. Bono, R.E. Sanborn, E.J. Lipson, M.K. Callahan, T. Gajewski, C.A. Gomez-Roca, F.S. Hodi, G. Curigliano, M. Nyakas, M. Preusser, Y. Koguchi, M. Maurer, R. Clynes, P. Mitra, S. Suryawanshi, E. Muñoz-Couselo, Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol 35, 9520–9520 (2017)
121.
J.M. Wang, Y.Q. Cheng, L. Shi, R.S. Ying, X.Y. Wu, G.Y. Li, J.P. Moorman, Z.Q. Yao, KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection. J Virol 87, 11626–11636 (2013)PubMedPubMedCentral
122.
B. Müller-Durovic, A. Lanna, L.P. Covre, R.S. Mills, S.M. Henson, A.N. Akbar, Killer cell lectin-like receptor G1 (KLRG1) inhibits NK cell function through activation of AMP-activated protein kinase. J Immunol 197, 2891–2899 (2016)PubMedPubMedCentral
123.
R. B. Delconte, T. B. Kolesnik, L. F. Dagley, J. Rautela, W. Shi, E. M. Putz, K. Stannard, J. G. Zhang, C. Teh, M. Firth, T. Ushiki, C. E. Andoniou, M. A. Degli-Esposti, P. P. Sharp, C. E. Sanvitale, G. Infusini, N. P. D. Liau, E. M. Linossi, C. J. Burns, S. Carotta, D. H. D. Gray, C. Seillet, D. S. Hutchinson, G. T. Belz, A. I. Webb, W. S. Alexander, S. S. Li, A. N. Bullock, J. J. Babon, M. J. Smyth, S. E. Nicholson, N. D. Huntington, CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol 17, 816–824 (2016)
124.
E.M. Putz, C. Guillerey, K. Kos, K. Stannard, K. Miles, R.B. Delconte, K. Takeda, S.E. Nicholson, N.D. Huntington, M.J. Smyth, Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. OncoImmunol 6, e1267892 (2017)
125.
E.C. So, A. Khaladj-Ghom, Y. Ji, J. Amin, Y. Song, E. Burch, H. Zhou, H. Sun, S. Chen, S. Bentzen, R. Hertzano, X. Zhang, S.E. Strome, NK cell expression of Tim-3: First impressions matter. Immunobiology. 224, 362–370 (2019)PubMed
126.
L.C. Ndhlovu, S. Lopez-Vergès, J.D. Barbour, R.B. Jones, A.R. Jha, B.R. Long, E.C. Schoeffler, T. Fujita, D.F. Nixon, L.L. Lanier, Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734–3743 (2012)
127.
L.Y. Xu, D.D. Chen, J.Y. He, C.C. Lu, X.G. Liu, H.B. Le, C.Y. Wang, Y.K. Zhang, Tim-3 expression by peripheral natural killer cells and natural killer T cells increases in patients with lung cancer--reduction after surgical resection. Asian Pac J Cancer Prev 15, 9945–9948 (2014)PubMed
128.
L. Xu, Y. Huang, L. Tan, W. Yu, D. Chen, C. Lu, J. He, G. Wu, X. Liu, Y. Zhang, Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29, 635–641 (2015)PubMed
129.
E. Batlle, J. Massagué, Transforming growth factor-β signaling in immunity and Cancer. Immunity 50, 924–940 (2019)
130.
S. Colak, P. Ten Dijke, Targeting TGF-β signaling in Cancer. Trends Cancer 3, 56–71 (2017)PubMed
131.
R. Trotta, J. Dal Col, J. Yu, D. Ciarlariello, B. Thomas, X. Zhang, J. Allard, M. Wei, H. Mao, J.C. Byrd, D. Perrotti, M.A. Caligiuri, TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 181, 3784–3792 (2008)PubMedPubMedCentral
132.
B. Han, F.Y. Mao, Y.L. Zhao, Y.P. Lv, Y.S. Teng, M. Duan, W. Chen, P. Cheng, T.T. Wang, Z.Y. Liang, J.Y. Zhang, Y.G. Liu, G. Guo, Q.M. Zou, Y. Zhuang, L.S. Peng, Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res 2018, 6248590 (2018)
133.
Y. Gao, F. Souza-Fonseca-Guimaraes, T. Bald, S.S. Ng, A. Young, S.F. Ngiow, J. Rautela, J. Straube, N. Waddell, S.J. Blake, J. Yan, L. Bartholin, J.S. Lee, E. Vivier, K. Takeda, M. Messaoudene, L. Zitvogel, M.W.L. Teng, G.T. Belz, C.R. Engwerda, N.D. Huntington, K. Nakamura, M. Hölzel, M.J. Smyth, Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol 18, 1004–1015 (2017)PubMed
134.
A. Dahmani, J.S. Delisle, TGF-β in T cell biology: Implications for cancer immunotherapy. Cancers 10, 6 (2018)
135.
H. Li, Y. Han, Q. Guo, M. Zhang, X. Cao, Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182, 240–249 (2009)PubMed
136.
Z. Li, Y. Pang, S.K. Gara, B.R. Achyut, C. Heger, P.K. Goldsmith, S. Lonning, L. Yang, Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression. Int J Cancer 131, 2584–2595 (2012)PubMedPubMedCentral
137.
Z.G. Fridlender, J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G.S. Worthen, S.M. Albelda, Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16, 183–119 (2009)PubMedPubMedCentral
138.
J.C. Mbongue, D.A. Nicholas, T.W. Torrez, N.S. Kim, A.F. Firek, W.H.R. Langridge, The role of Indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines 3, 703–729 (2015)PubMedPubMedCentral
139.
M. Foroutan, J. Cursons, S. Hediyeh-Zadeh, E.W. Thompson, M.J. Davis, A transcriptional program for detecting TGFβ-induced EMT in cancer. Mol Cancer Res 15, 619–631 (2017)
140.
S. Viel, A. Marçais, F.S.F. Guimaraes, R. Loftus, J. Rabilloud, M. Grau, S. Degouve, S. Djebali, A. Sanlaville, E. Charrier, J. Bienvenu, J.C. Marie, C. Caux, J. Marvel, L. Town, N.D. Huntington, L. Bartholin, D. Finlay, M.J. Smyth, T. Walzer, TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 9, 415 (2016)
141.
V. Zaiatz-Bittencourt, D.K. Finlay, C.M. Gardiner, Canonical TGF-β signaling pathway represses human NK cell metabolism. J Immunol 200, 3934–3941 (2018)PubMed
142.
L. Antonioli, C. Blandizzi, P. Pacher, G. Haskó, Immunity, inflammation and cancer: A leading role for adenosine. Nat Rev Cancer 13, 842–857 (2013)PubMed
143.
J. Stagg, M.J. Smyth, Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29, 5346–5358 (2010)
144.
145.
A. Young, D. Mittal, J. Stagg, M.J. Smyth, Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov 4, 879–888 (2014)PubMed
146.
A. Young, S.F. Ngiow, D.S. Barkauskas, E. Sult, C. Hay, S.J. Blake, Q. Huang, J. Liu, K. Takeda, M.W. Teng, Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30, 391–403 (2016)PubMed
147.
J. Wang, S. Matosevic, Adenosinergic signaling as a target for natural killer cell immunotherapy. J Mol Med 96, 903–913 (2018)PubMed
148.
A. Greenhough, H.J.M. Smartt, A.E. Moore, H.R. Roberts, A.C. Williams, C. Paraskeva, A. Kaidi, The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30, 377–386 (2009)
149.
150.
S. Zelenay, A. G. van der Veen, J. P. Böttcher, K. J. Snelgrove, N. Rogers, S. E. Acton, P. Chakravarty, M. R. Girotti, R. Marais, S. A. Quezada, E. Sahai, C. Reis e Sousa, Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015)
151.
D. Wang, R.N. DuBois, The role of prostaglandin E(2) in tumor-associated immunosuppression. Trends Mol Med 22, 1–3 (2016)PubMed
152.
J. Ke, Y. Yang, Q. Che, F. Jiang, H. Wang, Z. Chen, M. Zhu, H. Tong, H. Zhang, X. Yan, X. Wang, F. Wang, Y. Liu, C. Dai, X. Wan, Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer. Tumour Biol 37, 12203–12211 (2016)PubMedPubMedCentral
153.
B.C. Lee, H.S. Kim, T.H. Shin, I. Kang, J.Y. Lee, J.J. Kim, H.K. Kang, Y. Seo, S. Lee, K.R. Yu, S.W. Choi, K.S. Kang, PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact. Sci Rep 6, 26298 (2016)PubMedPubMedCentral
154.
155.
C.H.M.J. Van Elssen, J. Vanderlocht, T. Oth, B.L.M.G. Senden-Gijsbers, W.T.V. Germeraad, G.M.J. Bos, Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood 118, 2473–2482 (2011)
156.
J. P. Böttcher, E. Bonavita, P. Chakravarty, H. Blees, M. Cabeza-Cabrerizo, S. Sammicheli, N. C. Rogers, E. Sahai, S. Zelenay, C. Reis e Sousa. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037 (2018)
157.
M.Y. Jung, H.S. Kuehn, M. Beaven, D. Metcalfe, A. Gilfillan, Prostaglandin E2 induces activation of mTORC1 and mTORC2 in mast cells: Selective utilization of mTORC2 for the regulation of chemotaxis and mediator release. J Immunol 186, 151.6–151.6 (2011)
158.
D. Holt, X. Ma, N. Kundu, P.D. Collin, A.M. Fulton, Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 35, 179–188 (2012)PubMedPubMedCentral
159.
S. Ganapathy-Kanniappan, J.F.H. Geschwind, Tumor glycolysis as a target for cancer therapy: Progress and prospect. Mol Cancer 12, 152 (2013)PubMedPubMedCentral
160.
Z. Husain, Y. Huang, P. Seth, V.P. Sukhatme, Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. J Immunol 191, 1486–1495 (2013)PubMed
161.
A. Brand, K. Singer, G. E. Koehl, M. Kolitzus, G. Schoenhammer, A. Thiel, C. Matos, C. Bruss, S. Klobuch, K. Peter, M. Kastenberger, C. Bogdan, U. Schleicher, A. Mackensen, E. Ullrich, S. Fichtner-Feigl, R. Kesselring, M. Mack, U. Ritter, M. Schmid, C. Blank, K. Dettmer, P. J. Oefner, P. Hoffmann, S. Walenta, E. K. Geissler, J. Pouyssegur, A. Villunger, A. Steven, B. Seliger, S. Schreml, S. Haferkamp, E. Kohl, S. Karrer, M. Berneburg, W. Herr, W. Mueller-Klieser, K. Renner, M. Kreutz, LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24, 657–671 (2016)
162.
V. Huber, C. Camisaschi, A. Berzi, S. Ferro, L. Lugini, T. Triulzi, A. Tuccitto, E. Tagliabue, C. Castelli, L. Rivoltini, Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol 43, 74–89 (2017)PubMed
163.
N. Rohani, L. Hao, M.S. Alexis, B.A. Joughin, K. Krismer, M.N. Moufarrej, A.R. Soltis, D.A. Lauffenburger, M.B. Yaffe, C.B. Burge, S.N. Bhatia, F.B. Gertler, Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes. Cancer Res 79, 1952–1966 (2019)PubMedPubMedCentral
164.
Y. Long, Z. Gao, X. Hu, F. Xiang, Z. Wu, J. Zhang, X. Han, L. Yin, J. Qin, L. Lan, F. Yin, Y. Wang, Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma. Cancer Med 7, 4690–4700 (2018)
165.
E. Wennerberg, V Kremer, R. Childs, A. Lundqvist. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother 64, 225–235 (2015)
166.
V. Kremer, M.A. Ligtenberg, R. Zendehdel, C. Seitz, A. Duivenvoorden, E. Wennerberg, E. Colón, A.H. Scherman-Plogell, A. Lundqvist, Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer 5, 73 (2017)PubMedPubMedCentral
167.
M. Wendel, I.E. Galani, E. Suri-Payer, A. Cerwenka, Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68, 8437–8445 (2008)PubMed
168.
A. Brech, T. Ahlquist, R.A. Lothe, H. Stenmark, Autophagy in tumour suppression and promotion. Mol Oncol 3, 366–375 (2009)PubMedPubMedCentral
169.
A.C. Kimmelman, E. White, Autophagy and Tumor Metabolism Cell Metab 25, 1037–1043 (2017)PubMed
170.
E.Y. Liu, K.M. Ryan, Autophagy and cancer--issues we need to digest. J Cell Sci 125, 2349–2358 (2012)PubMed
171.
T. Mgrditchian, T. Arakelian, J. Paggetti, M.Z. Noman, E. Viry, E. Moussay, K. Van Moer, S. Kreis, C. Guerin, S. Buart, Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Nat Acad Sci 114, E9271–E9279 (2017)PubMed
172.
I.K. Choi, R. Strauss, M. Richter, C.O. Yun, A. Lieber, Strategies to increase drug penetration in solid tumors. Front Oncol 3, 193 (2013)PubMedPubMedCentral
173.
Q.T. Le, G. Shi, H. Cao, D.W. Nelson, Y. Wang, E.Y. Chen, S. Zhao, C. Kong, D. Richardson, K.J. O’Byrne, A.J. Giaccia, A.C. Koong, Galectin-1: A link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23, 8932–8941 (2005)PubMed
174.
V. Sundblad, L.G. Morosi, J.R. Geffner, G.A. Rabinovich, Galectin-1: A Jack-of-all-trades in the resolution of acute and chronic inflammation. J Immunol 199, 3721–3730 (2017)PubMed
175.
L. Astorgues-Xerri, M.E. Riveiro, A. Tijeras-Raballand, M. Serova, C. Neuzillet, S. Albert, E. Raymond, S. Faivre, Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40, 307–319 (2014)PubMed
176.
R. Wu, T. Wu, K. Wang, S. Luo, Z. Chen, M. Fan, D. Xue, H. Lu, Q. Zhuang, X. Xu, Prognostic significance of galectin-1 expression in patients with cancer: A meta-analysis. Cancer Cell Int 18, 108 (2018)PubMedPubMedCentral
177.
J.M. Cousin, M.J. Cloninger, The role of Galectin-1 in Cancer progression, and synthetic multivalent Systems for the Study of Galectin-1. Int J Mol Sci 17, 1566 (2016)PubMedCentral
178.
F.C. Chou, H.Y. Chen, C.C. Kuo, H.K. Sytwu, Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci 19, 430 (2018)PubMedCentral
179.
G.J. Baker, P. Chockley, V.N. Yadav, R. Doherty, M. Ritt, S. Sivaramakrishnan, M.G. Castro, P.R. Lowenstein, Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res 74, 5079–5090 (2014)PubMedPubMedCentral
180.
G.J. Baker, P. Chockley, D. Zamler, M.G. Castro, P.R. Lowenstein, Natural killer cells require monocytic gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunol 5, e1163461 (2016)
181.
J. Park, S.H. Wrzesinski, E. Stern, M. Look, J. Criscione, R. Ragheb, S.M. Jay, S.L. Demento, A. Agawu, P. Licona Limon, A.F. Ferrandino, D. Gonzalez, A. Habermann, R.A. Flavell, T.M. Fahmy, Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 11, 895–905 (2012)PubMedPubMedCentral
182.
F. Otegbeye, E. Ojo, S. Moreton, N. Mackowski, D.A. Lee, M. de Lima, D.N. Wald, Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One 13, e0191358 (2018)PubMedPubMedCentral
183.
A. Young, S.F. Ngiow, Y. Gao, A.M. Patch, D.S. Barkauskas, M. Messaoudene, G. Lin, J.D. Coudert, K.A. Stannard, L. Zitvogel, A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res 78, 1003–1016 (2018)PubMed
184.
J. Wang, K.B. Lupo, A.M. Chambers, S. Matosevic, Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer 6, 136 (2018)PubMedPubMedCentral
185.
O.E. Franco, A.K. Shaw, D.W. Strand, S.W. Hayward, Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21, 33–39 (2010)PubMed
186.
M. Augsten, Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 4, 62 (2014)PubMedPubMedCentral
187.
G. Valcz, F. Sipos, Z. Tulassay, B. Molnar, Y. Yagi, Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. J Clin Pathol 67, 1026–1031 (2014)PubMed
188.
T. Li, S. Yi, W. Liu, C. Jia, G. Wang, X. Hua, Y. Tai, Q. Zhang, G. Chen, Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med Oncol 30, 663 (2013)PubMed
189.
M. Balsamo, F. Scordamaglia, G. Pietra, C. Manzini, C. Cantoni, M. Boitano, P. Queirolo, W. Vermi, F. Facchetti, A. Moretta, L. Moretta, M.C. Mingari, M. Vitale, Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A 106, 20847–20852 (2009)PubMedPubMedCentral
190.
T. Inoue, K. Adachi, K. Kawana, A. Taguchi, T. Nagamatsu, A. Fujimoto, K. Tomio, A. Yamashita, S. Eguchi, H. Nishida, H. Nakamura, M. Sato, M. Yoshida, T. Arimoto, O. Wada-Hiraike, K. Oda, Y. Osuga, T. Fujii, Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor. International J Oncol 49, 1297–1304 (2016)
191.
R. Zhang, F. Qi, F. Zhao, G. Li, S. Shao, X. Zhang, L. Yuan, Y. Feng, Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis 10, 273 (2019)PubMedPubMedCentral
192.
R. Francescone, D. B. Vendramini-Costa, J. Franco-Barraza, J. Wagner, A. Muir, A. N. Lau, L. Gabitova, T. Pazina, S. Gupta, T. Luong, N. Shah, D. Rollins, R. Malik, R. Thapa, D. Restifo, Y. Zhou, K. Q. Cai, H. H. Hensley, Y. Tan, W. D. Kruger, K. Devarajan, S. Balachandran, W. S. El-Deiry, M. G. V. Heiden, S. Peri, K. S. Campbell, I. Astsaturov, E. Cukierman. The NetrinG1/NGL-1 Axis promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression. BioRxiv 330209 (2019)
193.
M.H. Townsend, G. Shrestha, R.A. Robison, K.L. O’Neill, The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res 37, 163 (2018)PubMedPubMedCentral
194.
L.C.S. Wang, A. Lo, J. Scholler, J. Sun, R.S. Majumdar, V. Kapoor, M. Antzis, C.E. Cotner, L.A. Johnson, A.C. Durham, C.C. Solomides, C.H. June, E. Puré, S.M. Albelda, Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2, 154–166 (2014)
195.
Y.J. Xie, M. Dougan, N. Jailkhani, J. Ingram, T. Fang, L. Kummer, N. Momin, N. Pishesha, S. Rickelt, R.O. Hynes, H. Ploegh, Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A 116, 7624–7631 (2019)PubMedPubMedCentral
196.
A. Lo, L.C.S. Wang, J. Scholler, J. Monslow, D. Avery, K. Newick, S. O’Brien, R.A. Evans, D.J. Bajor, C. Clendenin, A.C. Durham, E.L. Buza, R.H. Vonderheide, C.H. June, S.M. Albelda, E. Puré, Tumor-promoting Desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 75, 2800–2810 (2015)PubMedPubMedCentral
197.
A. O’Connell, S. Wang, L.M. Weiner, Abstract A096: The potential role of fibroblast activation protein as a natural killer cell immune checkpoint. Cancer Immunol Res 7, A096–A096 (2019)
198.
C. Hutmacher, N. Núñez, A.R. Liuzzi, B. Becher, D. Neri, Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8+ T cells. Cancer Immunol. Res 7, 572–583 (2019)
199.
M. Moschetta, F. Pretto, A. Berndt, K. Galler, P. Richter, A. Bassi, P. Oliva, E. Micotti, G. Valbusa, K. Schwager, M. Kaspar, E. Trachsel, H. Kosmehl, M.R. Bani, D. Neri, R. Giavazzi, Paclitaxel enhances therapeutic efficacy of the F8-IL2 Immunocytokine to EDA-fibronectin–positive metastatic human melanoma xenografts. Cancer Res 72, 1814–1824 (2012)PubMed
200.
J. Tchou, Y. Zhao, B.L. Levine, P.J. Zhang, M.M. Davis, J.J. Melenhorst, I. Kulikovskaya, A.L. Brennan, X. Liu, S.F. Lacey, A.D. Posey, A.D. Williams, A. So, J.R. Conejo-Garcia, G. Plesa, R.M. Young, S. McGettigan, J. Campbell, R.H. Pierce, J.M. Matro, A.M. DeMichele, A.S. Clark, L.J. Cooper, L.M. Schuchter, R.H. Vonderheide, C.H. June, Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 5, 1152–1161 (2017)
201.
A. Klampatsa, D.Y. Achkova, D.M. Davies, A.C. Parente-Pereira, N. Woodman, J. Rosekilly, G. Osborne, T. Thayaparan, A. Bille, M. Sheaf, J.F. Spicer, J. King, J. Maher, Intracavitary “T4 immunotherapy” of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett 393, 52–59 (2017)PubMed
202.
S.J. Priceman, D. Tilakawardane, B. Jeang, B. Aguilar, J.P. Murad, A.K. Park, W.C. Chang, J.R. Ostberg, J. Neman, R. Jandial, J. Portnow, S.J. Forman, C.E. Brown, Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast Cancer metastasis to the brain. Clin Cancer Res 24, 95–105 (2018)PubMed
203.
A. Nellan, C. Rota, R. Majzner, C.M. Lester-McCully, A.M. Griesinger, J.M. Mulcahy Levy, N.K. Foreman, K.E. Warren, D.W. Lee, Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6, 30 (2018)PubMedPubMedCentral
204.
S.C. Katz, G.R. Point, M. Cunetta, M. Thorn, P. Guha, N.J. Espat, C. Boutros, N. Hanna, R.P. Junghans, Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther 23, 142–148 (2016)PubMedPubMedCentral
205.
S. Genßler, M.C. Burger, C. Zhang, S. Oelsner, I. Mildenberger, M. Wagner, J.P. Steinbach, W.S. Wels, Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunol 5, e1119354 (2016)
206.
C. Zhang, M.C. Burger, L. Jennewein, S. Genßler, K. Schönfeld, P. Zeiner, E. Hattingen, P.N. Harter, M. Mittelbronn, T. Tonn, J.P. Steinbach, W.S. Wels, ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst 108(5) (2016)
207.
J. Han, J. Chu, W. Keung Chan, J. Zhang, Y. Wang, J.B. Cohen, A. Victor, W.H. Meisen, S.H. Kim, P. Grandi, Q.E. Wang, X. He, I. Nakano, E.A. Chiocca, J.C. Glorioso Iii, B. Kaur, M.A. Caligiuri, J. Yu, CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 5, 11483 (2016)
208.
X. Chen, J. Han, J. Chu, L. Zhang, J. Zhang, C. Chen, L. Chen, Y. Wang, H. Wang, L. Yi, J.B. Elder, Q.E. Wang, X. He, B. Kaur, E.A. Chiocca, J. Yu, A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 7, 27764–27777 (2016)PubMedPubMedCentral
209.
V. Bachanova, S. Cooley, T.E. Defor, M.R. Verneris, B. Zhang, D.H. McKenna, J. Curtsinger, A. Panoskaltsis-Mortari, D. Lewis, K. Hippen, P. McGlave, D.J. Weisdorf, B.R. Blazar, J.S. Miller, Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123, 3855–3863 (2014)
210.
E. Liu, Y. Tong, G. Dotti, H. Shaim, B. Savoldo, M. Mukherjee, J. Orange, X. Wan, X. Lu, A. Reynolds, M. Gagea, P. Banerjee, R. Cai, M.H. Bdaiwi, R. Basar, M. Muftuoglu, L. Li, D. Marin, W. Wierda, M. Keating, R. Champlin, E. Shpall, K. Rezvani, Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520–531 (2017)PubMedPubMedCentral
211.
P.W. Stacpoole, Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) Axis in Cancer. J Natl Cancer Inst 109, 11 (2017)
212.
N. Assmann, K.L. O’Brien, R.P. Donnelly, L. Dyck, V. Zaiatz-Bittencourt, R.M. Loftus, P. Heinrich, P.J. Oefner, L. Lynch, C.M. Gardiner, K. Dettmer, D.K. Finlay, Srebp-controlled glucose metabolism is essential for NK cell functional responses. Nat Immunol 18, 1197–1206 (2017)PubMed
213.
M. Sukumar, J. Liu, Y. Ji, M. Subramanian, J.G. Crompton, Z. Yu, R. Roychoudhuri, D.C. Palmer, P. Muranski, E.D. Karoly, R.P. Mohney, C.A. Klebanoff, A. Lal, T. Finkel, N.P. Restifo, L. Gattinoni, Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123, 4479–4488 (2013)PubMedPubMedCentral
214.
J.G. Crompton, M. Sukumar, R. Roychoudhuri, D. Clever, A. Gros, R.L. Eil, E. Tran, K.I. Hanada, Z. Yu, D.C. Palmer, S.P. Kerkar, R.D. Michalek, T. Upham, A. Leonardi, N. Acquavella, E. Wang, F.M. Marincola, L. Gattinoni, P. Muranski, M.S. Sundrud, C.A. Klebanoff, S.A. Rosenberg, D.T. Fearon, N.P. Restifo, Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 75, 296–305 (2015)PubMed
215.
O.U. Kawalekar, R.S. O’Connor, J.A. Fraietta, L. Guo, S.E. McGettigan, A.D. Posey, P.R. Patel, S. Guedan, J. Scholler, B. Keith, N.W. Snyder, I.A. Blair, M.C. Milone, C.H. June, Distinct signaling of Coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 44, 380–390 (2016)PubMed
216.
E.M. McWilliams, J.M. Mele, C. Cheney, E.A. Timmerman, F. Fiazuddin, E.J. Strattan, X. Mo, J.C. Byrd, N. Muthusamy, F.T. Awan, Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunol 5, e1226720 (2016)
217.
T.N. Dao, S. Matosevic, Immunometabolic responses of natural killer cells to inhibitory tumor microenvironment checkpoints. Immunometabolism 1, e20190003 (2019)
218.
M. Shevtsov, G. Multhoff, Immunological and translational aspects of NK cell-based antitumor immunotherapies. Front Immunol 7, 492 (2016)PubMedPubMedCentral
219.
220.
M. Turcotte, K. Spring, S. Pommey, G. Chouinard, I. Cousineau, J. George, G.M. Chen, D.M. Gendoo, B. Haibe-Kains, T. Karn, CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res 75, 4494–4503 (2015)PubMed
221.
Z. Gao, H. Wang, F. Lin, X. Wang, M. Long, H. Zhang, K. Dong, CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. BMC Cancer 17, 135 (2017)PubMedPubMedCentral
222.
S. Loi, S. Pommey, B. Haibe-Kains, P.A. Beavis, P.K. Darcy, M.J. Smyth, J. Stagg, CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 110, 11091–11096 (2013)PubMedPubMedCentral
223.
M. Lupia, F. Angiolini, G. Bertalot, S. Freddi, K.F. Sachsenmeier, E. Chisci, B. Kutryb-Zajac, S. Confalonieri, R.T. Smolenski, R. Giovannoni, CD73 regulates Stemness and epithelial-mesenchymal transition in ovarian Cancer-initiating cells. Stem Cell Rep 10, 1412–1425 (2018)
224.
L. Antonioli, C. Blandizzi, F. Malavasi, D. Ferrari, G. Haskó, Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment. Oncoimmunol 5, e1216292 (2016)
225.
J. C. Geoghegan, G. Diedrich, X. Lu, K. Rosenthal, K. F. Sachsenmeier, H. Wu, W. F. Dall’Acqua, M. M. Damschroder, Inhibition of CD73 AMP hhydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs 8, 454–467 (2016)
226.
I. Perrot, H.A. Michaud, M. Giraudon-Paoli, S. Augier, A. Docquier, L. Gros, R. Courtois, C. Déjou, D. Jecko, O. Becquart, H. Rispaud-Blanc, L. Gauthier, B. Rossi, S. Chanteux, N. Gourdin, B. Amigues, A. Roussel, A. Bensussan, J.F. Eliaou, J. Bastid, F. Romagné, Y. Morel, E. Narni-Mancinelli, E. Vivier, C. Paturel, N. Bonnefoy, Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27, 2411–2425 (2019)
227.
H.R. Lee, C.H. Son, E.K. Koh, J.H. Bae, C.D. Kang, K. Yang, Y.S. Park, Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Sci Rep 7, 11075 (2017)PubMedPubMedCentral
228.
S. Kumar, Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology 154, 383–393 (2018)
229.
M. Sabry, A. Zubiak, S.P. Hood, P. Simmonds, H. Arellano-Ballestero, E. Cournoyer, M. Mashar, A.G. Pockley, M.W. Lowdell, Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. PLoS One 14, e0218674 (2019)PubMedPubMedCentral
230.
M. Felices, T.R. Lenvik, Z.B. Davis, J.S. Miller, D.A. Vallera, Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol 1441, 333–346 (2016)PubMedPubMedCentral
231.
J.U. Schmohl, M. Felices, E. Taras, J.S. Miller, D.A. Vallera, Enhanced ADCC and NK cell activation of an Anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther 24, 1312–1322 (2016)PubMedPubMedCentral
232.
D.A. Vallera, M. Felices, R. McElmurry, V. McCullar, X. Zhou, J.U. Schmohl, B. Zhang, A.J. Lenvik, A. Panoskaltsis-Mortari, M.R. Verneris, J. Tolar, S. Cooley, D.J. Weisdorf, B.R. Blazar, J.S. Miller, IL15 Trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res 22, 3440–3450 (2016)PubMedPubMedCentral
233.
L. Gauthier, A. Morel, N. Anceriz, B. Rossi, A. Blanchard-Alvarez, G. Grondin, S. Trichard, C. Cesari, M. Sapet, F. Bosco, H. Rispaud-Blanc, F. Guillot, S. Cornen, A. Roussel, B. Amigues, G. Habif, F. Caraguel, S. Arrufat, R. Remark, F. Romagné, Y. Morel, E. Narni-Mancinelli, E. Vivier, Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell 177, 1701–1713 (2019)
234.
X. Yuan, H. Wu, H. Bu, J. Zhou, H. Zhang, Targeting the immunity protein kinases for immuno-oncology. Eur J Med Chem 163, 413–427 (2019)PubMed
235.
J.M. Yingling, W.T. McMillen, L. Yan, H. Huang, J.S. Sawyer, J. Graff, D.K. Clawson, K.S. Britt, B.D. Anderson, D.W. Beight, D. Desaiah, M.M. Lahn, K.A. Benhadji, M.J. Lallena, R.B. Holmgaard, X. Xu, F. Zhang, J.R. Manro, P.W. Iversen, C.V. Iyer, R.A. Brekken, M.D. Kalos, K.E. Driscoll, Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget 9, 6659–6677 (2018)PubMed
236.
H.C. Tran, Z. Wan, M.A. Sheard, J. Sun, J.R. Jackson, J. Malvar, Y. Xu, L. Wang, R. Sposto, E.S. Kim, S. Asgharzadeh, R.C. Seeger, TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin. Cancer Res 23, 804–813 (2017)PubMed
237.
D. Vijayan, A. Young, M.W. Teng, M.J. Smyth, Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17, 709–724 (2017)PubMed
238.
R.D. Leone, L.A. Emens, Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6, 57 (2018)
239.
R.D. Leone, Y.C. Lo, J.D. Powell, A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comp Struct Biotechnol J 13, 265–272 (2015)
240.
M. Congreve, G.A. Brown, A. Borodovsky, M.L. Lamb, Targeting adenosine A2A receptor antagonism for treatment of cancer. Expert Opin Drug Discov 13, 997–1003 (2018)PubMed
241.
K. Sek, C. Mølck, G.D. Stewart, L. Kats, P.K. Darcy, P.A. Beavis, Targeting adenosine receptor signaling in Cancer immunotherapy. Int J Mol Sci 19, 12 (2018)
242.
P.A. Beavis, U. Divisekera, C. Paget, M.T. Chow, L.B. John, C. Devaud, K. Dwyer, J. Stagg, M.J. Smyth, P.K. Darcy, Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 110, 14711–14716 (2013)PubMedPubMedCentral
243.
A. Young, S.F. Ngiow, J. Madore, J. Reinhardt, J. Landsberg, A. Chitsazan, J. Rautela, T. Bald, D.S. Barkauskas, E. Ahern, N.D. Huntington, D. Schadendorf, G.V. Long, G.M. Boyle, M. Hölzel, R.A. Scolyer, M.J. Smyth, Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res 77, 4684–4696 (2017)PubMed
244.
R. Romee, J.W. Leong, T.A. Fehniger, Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica 2014, 205796 (2014)PubMedPubMedCentral
245.
N.D. Huntington, H. Puthalakath, P. Gunn, E. Naik, E.M. Michalak, M.J. Smyth, H. Tabarias, M.A. Degli-Esposti, G. Dewson, S.N. Willis, N. Motoyama, D.C.S. Huang, S.L. Nutt, D.M. Tarlinton, A. Strasser, Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol 8, 856–863 (2007)PubMedPubMedCentral
246.
E. Mortier, T. Woo, R. Advincula, S. Gozalo, A. Ma, IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205, 1213–1225 (2008)PubMedPubMedCentral
247.
R. Evans, J.A. Fuller, G. Christianson, D.M. Krupke, A.B. Troutt, IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations. Cell Immunol 179, 66–73 (1997)PubMed
248.
A.H. Pillet, J. Thèze, T. Rose, Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes. Hum Immunol 72, 1013–1017 (2011)PubMed
249.
R.J. Hennessy, K. Pham, R. Delconte, J. Rautela, P.D. Hodgkin, N.D. Huntington, Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions. J Leukoc Biol 105, 1341–1354 (2019)PubMed
250.
M. Strengell, S. Matikainen, J. Sirén, A. Lehtonen, D. Foster, I. Julkunen, T. Sareneva, IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 170, 5464–5469 (2003)PubMed
251.
E. Lusty, S.M. Poznanski, K. Kwofie, T.S. Mandur, D.A. Lee, C.D. Richards, A.A. Ashkar, IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Mol Immunol 88, 138–147 (2017)PubMed
252.
C.S. Henney, K. Kuribayashi, D.E. Kern, S. Gillis, Interleukin-2 augments natural killer cell activity. Nature 291, 335–338 (1981)
253.
R. Spolski, P. Li, W.J. Leonard, Biology and regulation of IL-2: From molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018)PubMed
254.
255.
T. Jiang, C. Zhou, S. Ren, Role of IL-2 in cancer immunotherapy. Oncoimmunol 5, e1163462 (2016)
256.
H. Choudhry, N. Helmi, W.H. Abdulaal, M. Zeyadi, M.A. Zamzami, W. Wu, M.M. Mahmoud, M.K. Warsi, M. Rasool, M.S. Jamal, Prospects of IL-2 in Cancer immunotherapy. Biomed Res Int 2018, 9056173 (2018)PubMedPubMedCentral
257.
T. Chinen, A.K. Kannan, A.G. Levine, X. Fan, U. Klein, Y. Zheng, G. Gasteiger, Y. Feng, J.D. Fontenot, A.Y. Rudensky, An essential role for the IL-2 receptor in Treg cell function. Nat Immunol 17, 1322–1333 (2016)PubMedPubMedCentral
258.
D.H. Charych, U. Hoch, J.L. Langowski, S.R. Lee, M.K. Addepalli, P.B. Kirk, D. Sheng, X. Liu, P.W. Sims, L.A. VanderVeen, C.F. Ali, T.K. Chang, M. Konakova, R.L. Pena, R.S. Kanhere, Y.M. Kirksey, C. Ji, Y. Wang, J. Huang, T.D. Sweeney, S.S. Kantak, S.K. Doberstein, NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res 22, 680–690 (2016)PubMed
259.
V. Bachanova, J.S. Miller, NK cells in therapy of cancer. Crit Rev Oncog 19, 133–141 (2014)
260.
Z.B. Davis, M. Felices, M.R. Verneris, J.S. Miller, Natural killer cell adoptive transfer therapy: Exploiting the first line of defense against cancer. Cancer J 21, 486–491 (2015)
261.
S. Matosevic, Viral and nonviral engineering of natural killer cells as emerging adoptive Cancer immunotherapies. J Immunol Res 2018, 4054815 (2018)PubMedPubMedCentral
262.
Z. Wang, L. Guo, Y. Song, Y. Zhang, D. Lin, B. Hu, Y. Mei, D. Sandikin, H. Liu, Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D. Cancer Immunol Immunother 66, 537–548 (2017)PubMed
263.
W. Hu, G. Wang, D. Huang, M. Sui, Y. Xu, Cancer immunotherapy based on natural killer cells: Current Progress and new opportunities. Front Immunol 10, 1205 (2019)PubMedPubMedCentral
264.
Y. Li, D.L. Hermanson, B.S. Moriarity, D.S. Kaufman, Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181–192 (2018)PubMedPubMedCentral
265.
M. Naeimi Kararoudi, H. Dolatshad, P. Trikha, S.R.A. Hussain, E. Elmas, J.A. Foltz, J.E. Moseman, A. Thakkar, R.J. Nakkula, M. Lamb, N. Chakravarti, K.J. McLaughlin, D.A. Lee, Generation of Knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins. J Vis Exp 136, e58237 (2018)
266.
Q.M. Wang, P.M.K. Tang, G.Y. Lian, C. Li, J. Li, X.R. Huang, K. F. To, H.Y. Lan, Enhanced Cancer immunotherapy with Smad3-silenced NK-92 cells. Cancer Immunol Res 6, 965–977 (2018)
267.
E. S. Yvon, R. Burga, A. Powell, C. R. Cruz, R. Fernandes, C. Barese, T. Nguyen, M. S. Abdel-Baki, C. M. Bollard, Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy 19, 408–418 (n.d.)(107)
268.
R. Esser, T. Müller, D. Stefes, S. Kloess, D. Seidel, S.D. Gillies, C. Aperlo-Iffland, J.S. Huston, C. Uherek, K. Schönfeld, T. Tonn, N. Huebener, H.N. Lode, U. Koehl, W.S. Wels, NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 16, 569–581 (2012)PubMedPubMedCentral
269.
C. Sahm, K. Schönfeld, W.S. Wels, Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 61, 1451–1461 (2012)PubMed
270.
Y.H. Chang, J. Connolly, N. Shimasaki, K. Mimura, K. Kono, D. Campana, A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73, 1777–1786 (2013)PubMed
271.
R. Parihar, C. Rivas, M. Huynh, B. Omer, N. Lapteva, L.S. Metelitsa, S.M. Gottschalk, C.M. Rooney, NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res 7, 363–375 (2019)
272.
K. Schönfeld, C. Sahm, C. Zhang, S. Naundorf, C. Brendel, M. Odendahl, P. Nowakowska, H. Bönig, U. Köhl, S. Kloess, S. Köhler, H. Holtgreve-Grez, A. Jauch, M. Schmidt, R. Schubert, K. Kühlcke, E. Seifried, H.G. Klingemann, M.A. Rieger, T. Tonn, M. Grez, W.S. Wels, Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 23, 330–338 (2015)PubMed
273.
Q. Zhang, K. Tian, J. Xu, H. Zhang, L. Li, Q. Fu, D. Chai, H. Li, J. Zheng, Synergistic effects of Cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma. J Immunol Res 2017, 6915912 (2017)PubMedPubMedCentral
274.
M. Yu, H. Luo, M. Fan, X. Wu, B. Shi, S. Di, Y. Liu, Z. Pan, H. Jiang, Z. Li, Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther 26, 366–378 (2018)PubMed
275.
H. Park, A. Awasthi, J. Ayello, Y. Chu, S. Riddell, J. Rosenblum, D.A. Lee, M.S. Cairo, ROR1-specific chimeric antigen receptor (CAR) NK cell immunotherapy for high risk neuroblastomas and sarcomas. Biol Blood Marrow Transplant 23, S136–S137 (2017)
Metadata
Title
Functional and metabolic targeting of natural killer cells to solid tumors
Authors
Jiao Wang
Sandro Matosevic
Publication date
01-08-2020
Publisher
Springer Netherlands
Keyword
Solid Tumor
Published in
Cellular Oncology / Issue 4/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00523-7

Other articles of this Issue 4/2020

Cellular Oncology 4/2020 Go to the issue

Original paper

The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary

Original paper

LINC00858 knockdown inhibits gastric cancer cell growth and induces apoptosis through reducing WNK2 promoter methylation

Original paper

PFKP is highly expressed in lung cancer and regulates glucose metabolism

Original paper

Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations

Original paper

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis

Original paper

Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits